Distinct Epilepsy Phenotypes and Response to Drugs in KCNA1 Gain- and Loss-of Function Variants

Overview

Journal Epilepsia

Specialty Neurology

Date 2021 Nov 15

PMID 34778950

Citations 16

Authors

Francesco Miceli

Renzo Guerrini

Mario Nappi

Maria Virginia Soldovieri

Elena Cellini

Christina A Gurnett

Lucio Parmeggiani

Davide Mei

Maurizio Taglialatela

Affiliations

Soon will be listed here.

Abstract

A wide phenotypic spectrum of neurological diseases is associated with KCNA1 (Kv1.1) variants. To investigate the molecular basis of such a heterogeneous clinical presentation and identify the possible correlation with in vitro phenotypes, we compared the functional consequences of three heterozygous de novo variants (p.P403S, p.P405L, and p.P405S) in Kv1.1 pore region found in four patients with severe developmental and epileptic encephalopathy (DEE), with those of a de novo variant in the voltage sensor (p.A261T) identified in two patients with mild, carbamazepine-responsive, focal epilepsy. Patch-clamp electrophysiology was used to investigate the functional properties of mutant Kv1.1 subunits, both expressed as homomers and heteromers with wild-type Kv1.1 subunits. KCNA1 pore mutations markedly decreased (p. P405S) or fully suppressed (p. P403S, p. P405L) Kv1.1-mediated currents, exerting loss-of-function (LoF) effects. By contrast, channels carrying the p.A261T variant exhibited a hyperpolarizing shift of the activation process, consistent with a gain-of-function (GoF) effect. The present results unveil a novel correlation between in vitro phenotype (GoF vs LoF) and clinical course (mild vs severe) in KCNA1-related phenotypes. The excellent clinical response to carbamazepine observed in the patients carrying the A261T variant suggests an exquisite sensitivity of KCNA1 GoF to sodium channel inhibition that should be further explored.

Citing Articles

Voltage-gated potassium channels and genetic epilepsy.

Zheng Y, Chen J Front Neurol. 2024; 15:1466075.

PMID: 39434833 PMC: 11492950. DOI: 10.3389/fneur.2024.1466075.

Developmental and epileptic encephalopathies.

Scheffer I, Zuberi S, Mefford H, Guerrini R, McTague A Nat Rev Dis Primers. 2024; 10(1):61.

PMID: 39237642 DOI: 10.1038/s41572-024-00546-6.

Differential potassium channel inhibitory activities of a novel thermostable degradation peptide BmKcug1a-P1 from scorpion medicinal material and its N-terminal truncated/restored peptides.

Qin C, Yang X, Zuo Z, Yuan P, Sun F, Luo X Sci Rep. 2024; 14(1):16092.

PMID: 38997408 PMC: 11245557. DOI: 10.1038/s41598-024-66794-4.

Unusual Voltage-Gated Sodium and Potassium Channelopathies Related to Epilepsy.

Shin H, Ko A, Kim S, Lee J, Kang H J Clin Neurol. 2024; 20(4):402-411.

PMID: 38951973 PMC: 11220354. DOI: 10.3988/jcn.2023.0435.

Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights.

Ng A, Chahine M, Scantlebury M, Appendino J J Neurol. 2024; 271(6):3063-3094.

PMID: 38607431 DOI: 10.1007/s00415-024-12352-x.

References

Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D . Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes. Hum Mutat. 2016; 38(2):216-225. DOI: 10.1002/humu.23149. View

Russo A, Gobbi G, Pini A, Moller R, Rubboli G . Encephalopathy related to status epilepticus during sleep due to a de novo KCNA1 variant in the Kv-specific Pro-Val-Pro motif: phenotypic description and remarkable electroclinical response to ACTH. Epileptic Disord. 2020; 22(6):802-806. DOI: 10.1684/epd.2020.1222. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Peters C, Werry D, Gill H, Accili E, Fedida D . Mechanism of accelerated current decay caused by an episodic ataxia type-1-associated mutant in a potassium channel pore. J Neurosci. 2011; 31(48):17449-59. PMC: 6623802. DOI: 10.1523/JNEUROSCI.2940-11.2011. View

Imbrici P, Altamura C, Gualandi F, Mangiatordi G, Neri M, De Maria G . A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions. Mol Cell Neurosci. 2017; 83:6-12. DOI: 10.1016/j.mcn.2017.06.006. View

Bezanilla F . How membrane proteins sense voltage. Nat Rev Mol Cell Biol. 2008; 9(4):323-32. DOI: 10.1038/nrm2376. View

Syrbe S, Hedrich U, Riesch E, Djemie T, Muller S, Moller R . De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet. 2015; 47(4):393-399. PMC: 4380508. DOI: 10.1038/ng.3239. View

Miceli F, Soldovieri M, Ambrosino P, De Maria M, Migliore M, Migliore R . Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J Neurosci. 2015; 35(9):3782-93. PMC: 6605567. DOI: 10.1523/JNEUROSCI.4423-14.2015. View

Masnada S, Hedrich U, Gardella E, Schubert J, Kaiwar C, Klee E . Clinical spectrum and genotype-phenotype associations of KCNA2-related encephalopathies. Brain. 2017; 140(9):2337-2354. DOI: 10.1093/brain/awx184. View

10.

Browne D, Gancher S, Nutt J, Brunt E, Smith E, Kramer P . Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet. 1994; 8(2):136-40. DOI: 10.1038/ng1094-136. View

11.

Hedrich U, Lauxmann S, Wolff M, Synofzik M, Bast T, Binelli A . 4-Aminopyridine is a promising treatment option for patients with gain-of-function -encephalopathy. Sci Transl Med. 2021; 13(609):eaaz4957. DOI: 10.1126/scitranslmed.aaz4957. View

12.

Long S, Campbell E, MacKinnon R . Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science. 2005; 309(5736):903-8. DOI: 10.1126/science.1116270. View

13.

Eunson L, Rea R, Zuberi S, Youroukos S, Panayiotopoulos C, Liguori R . Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol. 2000; 48(4):647-56. View

14.

Niday Z, Tzingounis A . Potassium Channel Gain of Function in Epilepsy: An Unresolved Paradox. Neuroscientist. 2018; 24(4):368-380. PMC: 6045440. DOI: 10.1177/1073858418763752. View

15.

Liu X, Li C, Mou C, Dong Y, Tu Y . dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020; 12(1):103. PMC: 7709417. DOI: 10.1186/s13073-020-00803-9. View

16.

Du W, Bautista J, Yang H, Diez-Sampedro A, You S, Wang L . Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet. 2005; 37(7):733-8. DOI: 10.1038/ng1585. View

17.

Paulhus K, Ammerman L, Glasscock E . Clinical Spectrum of Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity. Int J Mol Sci. 2020; 21(8). PMC: 7215408. DOI: 10.3390/ijms21082802. View

18.

Chen X, Wang Q, Ni F, Ma J . Structure of the full-length Shaker potassium channel Kv1.2 by normal-mode-based X-ray crystallographic refinement. Proc Natl Acad Sci U S A. 2010; 107(25):11352-7. PMC: 2895106. DOI: 10.1073/pnas.1000142107. View

19.

Rogers A, Golumbek P, Cellini E, Doccini V, Guerrini R, Wallgren-Pettersson C . De novo KCNA1 variants in the PVP motif cause infantile epileptic encephalopathy and cognitive impairment similar to recurrent KCNA2 variants. Am J Med Genet A. 2018; 176(8):1748-1752. DOI: 10.1002/ajmg.a.38840. View

20.

Millichap J, Miceli F, De Maria M, Keator C, Joshi N, Tran B . Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant. Epilepsia. 2016; 58(1):e10-e15. PMC: 5219941. DOI: 10.1111/epi.13601. View